Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1101/2020.10.29.20222000 http://scihub22266oqcxt.onion/10.1101/2020.10.29.20222000 33184616!7658959!33184616     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       medRxiv 2020 ; ä (ä): ä Nephropedia Template TP {{tp|p=33184616|t=2020. Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus |pdf=|usr=}}{{33184616}} gab.com Text Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus JO: medRxiv http://www.kidney.de/pget.php?&tw=1&pmid=33184616 #FOAvip OBJECTIVES: Anti-type I interferon (IFN) autoantibodies have been reported in patients with systemic lupus erythematosus (SLE). Recently, an association of these autoantibodies with severe COVID-19 was reported in the general population. We assessed whether having pre-existing anti-IFNalpha autoantibodies was associated with COVID-19 infection in SLE patients. METHODS: Patients with SLE who developed COVID-19 between April 1(st) to October 1(st), 2020 were studied. Biobanked pre-COVID-19 plasma from these SLE subjects and healthy controls were tested for anti-IFNalpha IgG autoantibodies by ELISA. The ability of plasma anti-IFNalpha autoantibodies to block signal transducer and activator of transcription 1 (STAT1) phosphorylation by recombinant human IFNalpha in vitro was assessed by flow cytometry. RESULTS: Ten SLE subjects with COVID-19 were identified. A 40% of these subjects had stable autoantibodies against IFNalpha for up to three years preceding COVID-19 diagnosis. A 50% of the subjects with these autoantibodies neutralized IFNalpha induced STAT1 phosphorylation. None of the other SLE samples blocked IFNalpha signaling. CONCLUSIONS: We noted an increased prevalence of pre-existing anti-IFNalpha autoantibodies in SLE patients with COVID-19 compared to the reported prevalence in lupus patients and the general population with severe COVID-19. Autoantibodies against IFNalpha in SLE patients may be pathogenic and patients with them maybe at-risk of developing COVID-19. Twit Text FOAVip Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus ????medRxiv http://www.kidney.de/pget.php?&tw=1&pmid=33184616 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33184616 #FOAvip English Wikipedia <ref>{{Cite pmid|33184616}}</ref> Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus #MMPMID33184616 Gupta S; Nakabo S; Chu J; Hasni S; Kaplan MJ medRxiv 2020[Nov]; ä (ä): ä PMID33184616show ga OBJECTIVES: Anti-type I interferon (IFN) autoantibodies have been reported in patients with systemic lupus erythematosus (SLE). Recently, an association of these autoantibodies with severe COVID-19 was reported in the general population. We assessed whether having pre-existing anti-IFNalpha autoantibodies was associated with COVID-19 infection in SLE patients. METHODS: Patients with SLE who developed COVID-19 between April 1(st) to October 1(st), 2020 were studied. Biobanked pre-COVID-19 plasma from these SLE subjects and healthy controls were tested for anti-IFNalpha IgG autoantibodies by ELISA. The ability of plasma anti-IFNalpha autoantibodies to block signal transducer and activator of transcription 1 (STAT1) phosphorylation by recombinant human IFNalpha in vitro was assessed by flow cytometry. RESULTS: Ten SLE subjects with COVID-19 were identified. A 40% of these subjects had stable autoantibodies against IFNalpha for up to three years preceding COVID-19 diagnosis. A 50% of the subjects with these autoantibodies neutralized IFNalpha induced STAT1 phosphorylation. None of the other SLE samples blocked IFNalpha signaling. CONCLUSIONS: We noted an increased prevalence of pre-existing anti-IFNalpha autoantibodies in SLE patients with COVID-19 compared to the reported prevalence in lupus patients and the general population with severe COVID-19. Autoantibodies against IFNalpha in SLE patients may be pathogenic and patients with them maybe at-risk of developing COVID-19. äAssociation between anti-interferon-alpha autoantibodies and COVID-19 (epmc).pdf DeepDyve Pubget Overpricing